Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

Hormone tablets, abiraterone (Zytiga®) and enzalutamide (Xtandi®) are approved to treat advanced prostate cancer. However, even if these drugs are helpful, their effectiveness usually diminishes over time. Small pilot studies have indicated that using hormone tablets sparingly, for just long enough to control the cancer, followed by a break in treatment and restarting them later, seems to improve how long hormone tablets can control the cancer. This study aims to find out if this pause/restart strategy is better than taking hormone tablets every day continuously. The study will include 168 peo

Trial Details

NCT ID
NCT05393791
Phase
PHASE2
Sponsor
Leiden University Medical Center
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Patient-specific adaptive therapy
  • Abiraterone acetate
  • Enzalutamide
Locations (sample)
  • Albury, New South Wales, Australia|-36.07482,146.92401
  • Camperdown, New South Wales, Australia|-33.88965,151.17642
  • Kogarah, New South Wales, Australia|-33.9681,151.13564
  • Newcastle, New South Wales, Australia|-32.92953,151.7801
  • St Leonards, New South Wales, Australia|-33.82344,151.19836

Key Eligibility Criteria

  • Willing and able to provide informed consent;
  • Aged 18 or older;
  • Histologically or cytologically confirmed adenocarcinoma of the prostate;
  • Ongoing androgen deprivation therapy with a GnRH analogue or bilateral orchiectomy (i.e. surgical or medical castration with testosterone at screen…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →